Quick Facts / Company Snapshot
- Company Name: Waters Corporation
- Ticker Symbol: WAT
- Stock Exchange: New York Stock Exchange, Inc.
- Year Organized (Delaware): 1991
- Year of Initial Public Offering: 1995
- Total Net Sales (2025): $3,165,286,000
- Operating Income (2025): $802,588,000
- Net Income (2025): $642,629,000
- Employees (2025): Approximately 7,900
- Research & Development Personnel: Approximately 1,200
- Global Sales Offices: 82 (as of December 31, 2025)
- Field Representatives: Approximately 4,300
- Largest End Market: Pharmaceutical (59% of net sales)
- Total Assets (2025): $5,076,550,000
- Total Liabilities (2025): $2,515,308,000
- Major Business Segments: Waters and TA
- Waters Segment Revenue (2025): $2,813,446,000
- TA Segment Revenue (2025): $351,840,000
- Transformative Acquisition (2026): BD’s Biosciences and Diagnostic Solutions (BDS) for $16.8 billion
- Corporate Headquarters: 34 Maple Street, Milford, Massachusetts 01757
Company overview
Waters Corporation operates as a preeminent global leader in the realm of analytical instruments and software solutions. For over 65 years, the enterprise has pioneered innovations across chromatography, mass spectrometry, and thermal analysis. These technologies serve critical functions across the life, materials, and food sciences sectors.
- The primary focus revolves around designing, manufacturing, selling, and servicing high-performance and ultra-performance liquid chromatography systems.
- The technology portfolio extends deeply into mass spectrometry systems and specialized support products.
- Consumables, such as precision chromatography columns, form a massive recurring revenue base.
The operational framework of the enterprise is built around delivering integrated instrument systems that utilize common software platforms. The end-user base encompasses a diverse array of pharmaceutical, clinical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers. These clients leverage the technology for research and development, quality assurance, and rigorous laboratory applications.
- Liquid chromatography detects, identifies, monitors, and measures the chemical composition of materials.
- Mass spectrometry is heavily employed in drug discovery, clinical trial testing, and proteomics.
- Thermal analysis and rheometry instruments predict the stability of pharmaceuticals, polymers, and metals.
A massive structural shift occurred on February 9, 2026, when the enterprise completed the acquisition of the Biosciences and Diagnostic Solutions (BDS) business from Becton, Dickinson and Company. This $16.8 billion transformative combination positions the organization as an innovative global leader in both life sciences and diagnostics. The integration expands the capabilities into infectious disease detection, cancer diagnostics, and multiomics tools.
Business segments
The operational structure has historically been divided into two primary operating segments: Waters and TA. Following the massive BDS acquisition in early 2026, the organizational framework was restructured into four distinct segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. However, historical financial performance is categorized under the traditional two-segment model.
- Waters Segment Revenue (2025): $2,813,446,000
- Waters Segment Share: 88.88% of total net sales
- TA Segment Revenue (2025): $351,840,000
- TA Segment Share: 11.12% of total net sales
Waters Segment
The Waters operating segment focuses primarily on designing, manufacturing, selling, and servicing liquid chromatography (LC) and mass spectrometry (MS) instrument systems. This division also produces precision chemistry consumables, such as chromatography columns, that integrate seamlessly with various analytical instruments. Operations of the recently acquired Wyatt business are seamlessly integrated into this segment.
- Instrument systems generated $1,101,826,000 in 2025.
- Chemistry consumables contributed $631,458,000 in 2025.
- Service revenues reached $1,080,162,000 in 2025.
The segment leverages liquid chromatography as a standard technique to identify and analyze constituent components of diverse chemicals. The pharmaceutical industry represents the most significant end-use market, utilizing the technology to understand diseases and ensure drug purity. The segment also targets food and beverage safety, environmental testing, and clinical diagnostic applications.
TA Segment
The TA operating segment operates primarily in the business of designing, manufacturing, selling, and servicing thermal analysis, rheometry, and calorimetry instruments. These sophisticated tools measure the physical or thermodynamic characteristics of materials as a function of temperature. Changes in temperature alter a material’s heat flow, physical state, and mechanical properties, which these instruments precisely capture.
- TA instrument systems generated $243,816,000 in 2025.
- TA service revenues accounted for $108,024,000 in 2025.
- The segment serves material testing laboratories across plastics, chemicals, and electronics industries.
Rheometry instruments complement the thermal analyzers by characterizing the flow properties of materials. They measure viscosity, elasticity, and deformation under various loading conditions, providing crucial insights into how materials behave during processing, transport, and storage. The TA segment operates independently from the Waters segment, maintaining its own dedicated field sales and service operations.
History and evolution
Waters Corporation was organized as a Delaware corporation in 1991, functioning as a holding company that owns all outstanding common stock of its operating subsidiary, Waters Technologies Corporation. The enterprise transitioned into a publicly traded entity with its initial public offering in November 1995. Since entering the public markets, the organization has aggressively expanded its technological footprint through strategic acquisitions.
- TA Instruments was acquired in May 1996.
- Micromass Limited was integrated in September 1997.
- Wyatt Technology joined the portfolio in May 2023.
- On February 9, 2026, the $16.8 billion BDS Business Acquisition was finalized.
- The transaction was uniquely structured as a Reverse Morris Trust.
- Existing shareholders retained approximately 60.8% of the combined company.
The BDS Business Acquisition from Becton, Dickinson and Company represents the most transformative event in the corporate timeline. It expanded the operational scope into immunology, cancer research solutions, clinical diagnostics, and flow cytometry instruments. To facilitate this, the organization assumed $4.0 billion of indebtedness to fund a cash distribution prior to the completion of the transaction.
Products and services
The product architecture is categorized into instrument systems, chemistry consumables, and services. The total revenue generation across these lines emphasizes a balanced approach between high-value capital equipment and recurring revenue streams. In 2025, instrument system sales across both segments totaled $1,345,642,000. Chemistry consumables generated $631,458,000, while total service sales reached $1,188,186,000.
- Waters Instrument Systems: Contributed 34.81% to total net sales. Calculated from $1,101,826,000 out of $3,165,286,000.
- Waters Service: Contributed 34.12% to total net sales. Calculated from $1,080,162,000 out of $3,165,286,000.
- Chemistry Consumables: Contributed 19.95% to total net sales. Calculated from $631,458,000 out of $3,165,286,000.
- TA Instrument Systems: Contributed 7.70% to total net sales. Calculated from $243,816,000 out of $3,165,286,000.
- TA Service: Contributed 3.41% to total net sales. Calculated from $108,024,000 out of $3,165,286,000.
High-Performance and Ultra-Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) serves as the foundational technique used to identify the constituent components of chemicals. The technology separates, identifies, and quantifies a high proportion of all known chemicals. The introduction of ultra-performance liquid chromatography (UPLC) utilized packing material with small, uniform diameter particles to accommodate increased pressure and narrower chromatographic bands.
- UPLC achieves more comprehensive chemical separations and faster analysis times.
- The systems are compatible with general operating protocols of standard HPLC.
- Instrument configurations range from academic teaching setups to fully automated regulatory systems.
Mass Spectrometry
Mass spectrometry (MS) identifies unknown compounds and elucidates the structural properties of molecules by measuring the masses of molecules converted into ions. A wide variety of instrumental designs are offered, including quadrupole, ion trap, time-of-flight, and ion mobility technologies. These technologies are frequently used in tandem to maximize experimental speed and efficacy.
- The majority of mass spectrometers are designed to utilize an LC system as the sample introduction device.
- Smaller mass spectrometers operate essentially as advanced LC detectors.
- Larger systems focus on late-stage drug development and clinical trial testing.
Precision Chemistry Consumables
The primary consumable products for LC instruments are chromatography columns. These columns are packed with separation media, typically stationary phase particles made from silica or polymeric resins. As a pressurized sample permeates through the packed column, it separates into its constituent components.
- The portfolio includes environmental and nutritional safety testing products.
- The organization manufactures its own silica and polymeric resins.
- In-house manufacturing ensures product consistency for quality control laboratories.
Global Services
Services maximize technology productivity, support customer compliance activities, and provide transparency into enterprise resource management efficiencies. The servicing of instruments and software represents over 35% of the Waters segment sales. Revenues are derived from support plans, demand services, spare parts, performance validation, and customer training.
- Support plans involve scheduled instrument maintenance and prompt repair agreements.
- Software-as-a-Service applications enable real-time monitoring of chromatography instruments.
- TA services represented more than 25% of the TA segment’s sales in 2025.
Brand portfolio
The enterprise manages a robust portfolio of recognizable brands tailored to specific analytical requirements. While specific revenue per brand is not isolated from the broader segment data in the disclosures, their technological positioning is clearly defined.
ACQUITY UPLC System
The ACQUITY UPLC System revolutionized the chromatography landscape by utilizing highly specialized instruments to accommodate increased pressure. Researchers leverage this brand to uncover deeper levels of scientific information beyond standard HPLC capabilities. The system is deeply integrated with proprietary ACQUITY UPLC Columns.
Alliance iS HPLC System
Positioned as the next-generation intelligent HPLC system, the Alliance iS is designed to drastically reduce compliance risk. It introduces proactive error detection and troubleshooting. When combined with compliance-ready Empower software, the system streamlines accurate measurements by eliminating common operational errors.
Xevo Mass Spectrometers
The Xevo brand represents a line of highly sensitive mass spectrometers. The Xevo TQ Absolute IVD Mass Spectrometer is up to five times more sensitive for quantifying clinical analytes. The recently introduced Xevo TQ Absolute XR Mass Spectrometer exceeds previous benchmarks, utilizing up to 50% less power and nitrogen gas while producing 50% less heat.
Wyatt Technology
Acquired in 2023, the Wyatt brand anchors the light scattering and field-flow fractionation portfolio. Instruments like the DynaPro ZetaStar enable simultaneous dynamic and static light scattering measurements. This technology is critical for the precise development of complex biologics using extremely low sample volumes.
Geographical presence
The enterprise operates as a truly global entity, serving customers in over 35 countries. In 2025, approximately 69% of the total net sales originated outside of the United States. The geographical revenue distribution underscores a balanced reliance on the Americas, Europe, and Asia.
- Americas Total Revenue: $1,161,513,000. Contributes 36.70% to total net sales.
- Asia Total Revenue: $1,040,397,000. Contributes 32.87% to total net sales.
- Europe Total Revenue: $963,376,000. Contributes 30.43% to total net sales.
The Americas
The United States dominates the Americas region, generating $965,782,000 in net sales during 2025. Sales in the U.S. expanded by 3% in 2025, supported by broad-based customer demand. Other regions in the Americas generated $195,731,000, achieving an 8% growth rate. The organization maintains 20 facilities across the United States.
Asia
The Asian market presents a complex operational landscape. Total Asian sales hit $1,040,397,000 in 2025. China represents a critical sub-market, accounting for $437,468,000 in revenue, which reflects a 10% increase from the previous year. This recovery followed a 10% decline in 2024, which was triggered by macroeconomic challenges, increased competition, and government procurement restrictions.
- Other Asian markets generated $602,929,000 in 2025.
- Key manufacturing and support subcontractors are located in Singapore.
- The Singapore entity manages all Asian outsourced manufacturing.
Europe
Europe generated $963,376,000 in net sales during 2025, marking a robust 10% growth rate compared to 2024. The enterprise operates considerable manufacturing infrastructure within Europe. LC columns are manufactured in Wexford, Ireland, while mass spectrometry products are produced in Wilmslow and Birmingham, England.
Profit and loss
The consolidated statements of operations reflect the financial dynamics of the enterprise for the fiscal years ended December 31.
| Revenues and Expenses (in thousands, except per share data) | 2025 | 2024 | 2023 |
| Product sales | $1,977,100 | $1,844,176 | $1,903,050 |
| Service sales | $1,188,186 | $1,114,211 | $1,053,366 |
| Total net sales | $3,165,286 | $2,958,387 | $2,956,416 |
| Cost of sales | $1,288,822 | $1,200,201 | $1,195,223 |
| Selling and administrative expenses | $830,374 | $690,148 | $736,014 |
| Research and development expenses | $195,711 | $183,027 | $174,945 |
| Purchased intangibles amortization | $47,791 | $47,090 | $32,558 |
| Litigation provisions | $11,568 | $— | $— |
| Operating income | $802,588 | $826,353 | $817,676 |
| Other income, net | $3,061 | $776 | $807 |
| Interest expense, net | $(50,771) | $(72,261) | $(82,240) |
| Income before income taxes | $754,878 | $754,868 | $736,243 |
| Provision for income taxes | $112,249 | $117,034 | $94,009 |
| Net income | $642,629 | $637,834 | $642,234 |
| Net income per diluted common share | $10.76 | $10.71 | $10.84 |
Balance sheet
The consolidated balance sheets provide a snapshot of the corporate financial position.
| Assets (in thousands) | December 31, 2025 | December 31, 2024 |
| Cash and cash equivalents | $587,831 | $325,355 |
| Accounts receivable, net | $828,844 | $733,365 |
| Inventories | $572,371 | $477,261 |
| Other current assets | $158,599 | $133,130 |
| Total current assets | $2,147,645 | $1,669,111 |
| Property, plant and equipment, net | $642,046 | $651,200 |
| Intangible assets, net | $558,179 | $567,906 |
| Goodwill | $1,340,081 | $1,295,720 |
| Operating lease assets | $80,764 | $74,193 |
| Other assets | $307,835 | $295,665 |
| Total assets | $5,076,550 | $4,553,795 |
| Liabilities and Stockholders’ Equity (in thousands) | December 31, 2025 | December 31, 2024 |
| Notes payable and debt | $460,000 | $— |
| Accounts payable | $103,778 | $99,931 |
| Deferred revenue and customer advances | $266,540 | $250,807 |
| Total current liabilities | $1,239,499 | $789,758 |
| Long-term debt | $947,445 | $1,626,488 |
| Total long-term liabilities | $1,275,809 | $1,935,530 |
| Total liabilities | $2,515,308 | $2,725,288 |
| Common stock | $1,632 | $1,630 |
| Retained earnings | $10,431,284 | $9,788,655 |
| Treasury stock | $(10,162,460) | $(10,147,793) |
| Total stockholders’ equity | $2,561,242 | $1,828,507 |
Cash flow
The consolidated statements of cash flows detail the liquidity movements within the organization.
| Cash Flows (in thousands) | 2025 | 2024 | 2023 |
| Net cash provided by operating activities | $652,555 | $762,123 | $602,809 |
| Additions to property, plant, equipment, software | $(112,745) | $(142,481) | $(160,632) |
| Asset and business acquisitions, net | $(35,053) | $— | $(1,282,354) |
| Net cash used in investing activities | $(152,253) | $(143,089) | $(1,442,265) |
| Proceeds from debt issuances | $70,000 | $170,000 | $1,450,040 |
| Payments on debt | $(290,000) | $(900,000) | $(670,040) |
| Net cash (used in) provided by financing activities | $(237,205) | $(696,675) | $754,951 |
| Increase (decrease) in cash and cash equivalents | $262,476 | $(69,721) | $(85,453) |
Board of directors and leadership team
The corporate governance structure is helmed by experienced executives elected annually by the Board of Directors.
- Dr. Udit Batra: Appointed as Director, President, and Chief Executive Officer on September 1, 2020. Prior to this role, he served as CEO of the Life Science business of Merck KGaA, Darmstadt, Germany. Dr. Batra also oversaw the company’s Bioethics Advisory Panel and Information Technology function.
- Dr. Flemming Ornskov, M.D., M.P.H.: Serves as the Chair of the Board of Directors.
- Amol Chaubal: Serves as the Senior Vice President and Chief Financial Officer, acting as the Principal Financial Officer and Principal Accounting Officer.
Subsidiaries, associates, joint ventures
The corporate structure relies on a network of wholly-owned subsidiaries spanning the globe. Except as otherwise indicated, each subsidiary is wholly-owned by its immediate parent entity. Exact revenue contributions per subsidiary are not explicitly disclosed in the provided data.
- Waters Technologies Corporation (Delaware)
- Wyatt Technology, LLC (California)
- TA Instruments-Waters LLC (Delaware)
- Micromass Limited (UK)
- Environmental Resource Associates, Inc. (Colorado)
- Andrew Alliance SA (Switzerland)
- Optofludics, Inc. (d/b/a Halo Labs) (Delaware)
Other Investments (Including Minority / Portfolio Holdings)
The enterprise maintains cash balances in various operating accounts, with a portion held as cash equivalents. Cash equivalents represent highly liquid investments, with original maturities of 90 days or less.
- Investments include bank deposits, U.S. treasury bill money market funds, and commercial paper.
- Investments with maturities greater than 90 days are held primarily in corporate debt securities.
- No specific minority holdings, equity investments measured at fair value, or strategic venture capital portfolios are detailed within the disclosed information.
Physical properties (offices, plants, factories, etc.)
The organization operates an extensive physical footprint, encompassing 20 United States facilities and 70 international facilities, including field offices. The primary facilities serve specific operational functions ranging from manufacturing to research.
- Milford, Massachusetts: Serves as the primary research and development center. It houses manufacturing, research, sales, and administrative functions. The facility maintains rigorous ISO certifications.
- Taunton, Massachusetts: Focuses on manufacturing and research. The facility recently completed a massive $251 million expansion to process silica and polymeric media.
- Wexford, Ireland: Functions as a critical manufacturing, research, and distribution hub for LC, MS, and TA product lines.
- Wilmslow, England: Develops the majority of the mass spectrometry products. Dedicated to manufacturing, research, sales, distribution, and administration.
- New Castle, Delaware: Acts as the primary research and development center for materials characterization products.
- Santa Barbara, California: The exclusive manufacturing location for Wyatt products.
Investments and capital expenditure plans
Capital expenditure is a critical driver for sustaining technological leadership and operational capacity. The enterprise commits substantial resources to research and development and infrastructure enhancement.
- R&D spending hit $196 million in 2025.
- Capital expenditures related to property, plant, equipment, and software capitalization reached $113 million in 2025.
- A new worldwide enterprise resource planning (ERP) system was approved in December 2024.
- The total anticipated spend for the ERP implementation is approximately $130 million.
Strategic investments emphasize the development of novel technologies. For example, recent product introductions require significant time and spending before robust sales are realized. The organization also actively evaluates the deployment of artificial intelligence within its business operations and products.
Shareholding pattern
The enterprise’s common stock is registered under the Exchange Act and listed on the New York Stock Exchange under the symbol “WAT”. The exact breakdown of promoter, institutional, and public holdings is not detailed in the provided report.
- As of February 19, 2026, there were 5,058 common stockholders of record.
- The company has not paid any dividends since its IPO.
- A $1.0 billion share repurchase authorization remains available through January 21, 2028.
Future strategy
The future strategic orientation is heavily dominated by the monumental integration of the BDS Business. The primary focus involves realizing anticipated cost synergies of approximately $200 million within three years, driven by manufacturing and supply chain optimization. Furthermore, revenue synergies of $290 million are targeted within five years through cross-selling opportunities.
- The strategy necessitates streamlining commercial infrastructure and eliminating duplicative digital assets.
- A major transition to a new worldwide ERP system is underway to enhance operational scalability.
- Continuous innovation in LC-MS technologies remains central to organic growth.
Key strengths
The organizational resilience is built upon several foundational strengths supported by operational data.
- Massive Recurring Revenue Base: The servicing and support of instruments represented over 35% of sales for the Waters segment in 2025.
- Diversified Client Base: No single customer accounted for more than 2% of net sales during fiscal 2025.
- In-House Manufacturing Control: The entity is one of the few suppliers globally that processes its own silica and polymeric resins, ensuring unmatched product consistency.
- Direct Sales Model: The enterprise boasts one of the largest direct sales and service organizations, featuring approximately 4,300 field representatives.
Key challenges and risks
Despite strong market positioning, the enterprise navigates a complex web of operational and macroeconomic risks.
- Integration Risks: The $16.8 billion BDS Business Acquisition presents massive integration challenges, including potential cultural clashes and loss of key personnel.
- Debt Burden: The assumption of $4.0 billion in new indebtedness limits operational flexibility and increases borrowing costs.
- Chinese Market Volatility: Sales in China fell 10% in 2024 due to macroeconomic conditions, trade tensions, and tightening government procurement restrictions.
- Cybersecurity Threats: The technology infrastructure is vulnerable to ransomware and unauthorized access, which could disrupt the delivery of digital and web-based products.
- Supply Chain Disruptions: Reliance on sole-source suppliers for specialized components exposes the manufacturing process to risks from geopolitical developments and transportation delays.
Conclusion and strategic outlook
Waters Corporation remains a formidable entity within the high-stakes analytical instrument industry. The core business surrounding liquid chromatography and mass spectrometry continues to generate exceptional cash flow, supported by a sticky, recurring revenue model tied to chemistry consumables and deeply embedded service contracts. The unprecedented acquisition of the BDS Business marks a permanent pivot toward broader clinical diagnostics and life sciences dominance. While the massive debt assumption and integration complexities present near-term hurdles, the combined entity possesses the technological depth, global scale, and specialized workforce necessary to command an expanding share of the multiomics and precision medicine markets well into the next decade.
FAQ section
What are the primary products manufactured by Waters Corporation? The company primarily designs and manufactures high-performance liquid chromatography (HPLC) systems, mass spectrometry (MS) instruments, chemistry consumables like chromatography columns, and thermal analysis instruments.
How much revenue did the company generate in 2025? The company achieved total net sales of $3,165,286,000 during the 2025 fiscal year.
What was the most significant acquisition made by the company recently? On February 9, 2026, the company completed the $16.8 billion acquisition of the Biosciences and Diagnostic Solutions (BDS) business from Becton, Dickinson and Company.
How is the company’s revenue distributed geographically? In 2025, the Americas contributed roughly 36.7%, Asia contributed 32.8%, and Europe contributed 30.4% to the total net sales.
Does the company rely heavily on a single customer? No, the client base is highly diversified. No single customer accounted for more than 2% of the company’s net sales in 2025.
What are the main risks facing the company’s operations? Key risks include the successful integration of the massive BDS business, heavy debt burdens assumed for the acquisition, macroeconomic challenges within the Chinese market, and vulnerabilities to cybersecurity threats.
Official Site: https://www.waters.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
